Objectives: To develop reference ranges for platelet aggregation using the Multiplate analyzer (Roche Diagnostics, Mannheim, Germany) Conclusions: These data demonstrate the importance of establishing locally relevant reference ranges.
Platelet aggregation is used to detect both congenital and acquired disorders of primary hemostasis. The clinical demand for platelet function testing has risen with increases in the utilization of antiplatelet agents for the prevention of arterial thrombosis. Clinical laboratories are faced with significant challenges in performing platelet function testing, since traditional assays are complex and poorly standardized. 1 Preanalytical variables, including blood sampling, type of sample tested (whole blood or platelet-rich plasma), and anticoagulant matrix, have significant effects on in vitro platelet function. Moreover, depending on both time and temperature, 2,3 platelets undergo a shape change after the blood is drawn and may become increasingly sensitive to in vitro activation, followed by a refractory period. 4 In addition, platelet function studies conducted in platelet-rich plasma introduce an artifact by eliminating the interactions of platelets with red blood cells and white blood cells that occur in vivo. 5 Whole-blood platelet aggregation offers the advantage of examining platelet function in a more physiologic environment. 4 Anticoagulants represent a significant variable in platelet function testing. Different anticoagulants prevent blood clotting by different mechanisms, each creating a unique nonphysiologic setting that can modify platelet function. 6 Three major anticoagulants have been used for platelet function testing. Sodium citrate (Na-citrate), the traditional anticoagulant of choice, prevents blood coagulation by chelating calcium and may interfere with platelet responses to specific agonists due to the depletion of calcium ions essential for platelet activation. 7 Interestingly, Na-citrate has been reported to enhance platelet secretion and microaggregate formation. 8 In contrast, hirudin prevents blood coagulation by DOI: 10.1309/AJCPP43SEYCBJLHJ
© American Society for Clinical Pathology directly inhibiting thrombin. Physiologic levels of calcium are preserved, resulting in increased stability of platelet function. 7 However, this anticoagulant inhibits platelet-dense granule secretion in a concentration-dependent manner, and platelets respond differently in blood that has been anticoagulated with hirudin compared with either citrate or heparin. 9 Heparin anticoagulates blood by primarily inhibiting thrombin and factor Xa. It has been shown to induce the expression of adhesive protein receptors on the surface of the platelets, 10 thereby inducing platelet aggregation. 11 To optimize the interpretation of platelet function studies, it is important to establish relevant reference ranges and to understand assay precision, as well as the impact of preanalytical variables, especially the impact of the anticoagulant used. This study established reference ranges for whole-blood platelet aggregation in response to seven common agonists, using a large, ethnically diverse adult volunteer population whose blood was collected into three different anticoagulants. In addition, precision studies were performed using both normal and abnormal samples for all three anticoagulants and seven agonists. Since clinical laboratories are often limited by their ability to recruit ethnically diverse healthy volunteers for reference range studies, as well as the amount of blood required to perform precision studies, the data presented here will be useful to laboratories using the Multiplate analyzer (Roche Diagnostics, Mannheim, Germany) in their efforts to validate local wholeblood platelet aggregation reference ranges.
Materials and Methods

Study Group and Study Design
In this prospective multicenter study, fresh whole-blood samples were obtained from apparently healthy volunteers (n = 193). The study was conducted at one European Union (EU) site (Academic Medical Center, Amsterdam, The Netherlands) and two sites in the United States (Florida Hospital, Orlando, and Memorial Sloan Kettering Cancer Center, New York). The study was approved by the relevant institutional internal review boards in the United States and the ethics committee in the EU. Written informed consent was obtained from all study participants. The study population included healthy adult subjects 21 years or older from the US sites or 18 years or older from the EU site. Male and female subjects with diverse ethnic backgrounds were recruited. Health status was assessed by a questionnaire to demonstrate the absence of illness, bleeding, or thrombosis or the presence of anticoagulation therapy. All participants were free of platelet function-inhibiting medications in the 10 days preceding sample collection.
Blood Collection
Blood was collected into Na-citrate (13 × Participants rested for at least 10 minutes in a sitting or supine position before blood withdrawal. A tourniquet (or a blood pressure cuff) was applied for no longer than 2 minutes. Blood samples were collected in the following order: Na-citrate, hirudin, Li-heparin, and EDTA. The blood was mixed well and allowed to remain at room temperature for 30 minutes prior to platelet aggregation testing. All testing was completed within 3 hours. The EDTA sample was analyzed on each site's automated hematology analyzer for PLTC, Hb, and Hct. Blood samples were excluded from platelet function testing if the PLTC was less than 100 × 10 9 /L or Hct was less than 20%. No exclusion criteria were observed for thrombocytosis or increased Hct.
Precision studies were performed on blood samples with normal and reduced platelet function. Blood was collected from healthy participants not taking antiplatelet medications (normal platelet function) and from volunteers who had taken aspirin (abnormal platelet function). Participants receiving aspirin were on a daily aspirin regimen or had purposely ingested aspirin within the previous 24 hours for analgesic purposes. The minimum ingested aspirin dose was 81 mg. Due to the volume of blood required to perform precision studies and the window of time for testing, each site collected a total of six different donors as healthy participants and six different donors taking aspirin. Healthy volunteers and those who had ingested aspirin were not the same individuals.
To avoid bias, platelet aggregation testing in response to seven agonists was randomized to different aggregometer channels according to predetermined schematics. There were seven different randomization combinations that each site used in succession and then repeated as needed.
A total of 196 participants were consented. Three were excluded. One blood sample was clotted and two blood samples could not be obtained. The total number of participants enrolled in the study was 193. Aggregation studies were performed on a total of eight Multiplate analyzers: site 1 (n = 4 analyzers), site 2 (n = 2 analyzers), and site 3 (n = 2 analyzers). mg/mL). In addition, aggregation was performed with the combination of ADP (final concentration, 9.4 mmol/L) and prostaglandin E 1 (ADP HS) to isolate the P 2 Y 12 receptormediated platelet response. The latter agonist was tested only in blood samples collected in Li-heparin and hirudin as per the manufacturer's instructions. All reagents were supplied by Roche Diagnostics.
Statistical Analysis
The reference interval was determined by nonparametric analysis. All reports were generated using fully validated software SAS v9.3 (SAS Institute, Cary, NC). The P values calculated for this study were from the Kruskal-Wallis test for median differences between anticoagulants. A P value less than .05 was considered statistically significant.
Results
Whole-blood platelet aggregation was measured in 193 healthy volunteers (124 women and 69 men). Relevant participants had a mean age of 41 years (range, 21-71 years). Participant demographics are summarized in ❚Table 1❚ and ❚Table 2❚.
Results of precision studies (healthy participants and volunteers taking aspirin) for Multiplate whole-blood platelet aggregation across testing sites are shown in ❚Table 3❚. Coefficients of variation (CVs) were highest for blood samples with the weakest platelet responses, regardless of anticoagulant. Samples from individuals who had ingested aspirin demonstrated the highest imprecision when tested with ASPI, particularly if blood was anticoagulated with hirudin.
Pooled platelet aggregation results from all sites ❚Table 4❚ demonstrated statistically significant (P ≤ .0001) differences in platelet responses to all agonists, depending on the anticoagulant. Samples collected in Na-citrate demonstrated the lowest AUC for all agonists, whereas AUC values were highest for samples anticoagulated with Li-heparin. Reference range intervals for each agonist and anticoagulant combination are shown in ❚Figure 1❚. For all agonists, the difference between median values for the three anticoagulants was determined to be statistically significant (P < .0001).
❚Table 5❚ compares reference ranges for whole-blood platelet aggregation across testing sites. Statistically significant differences in reference ranges between sites were noted for many agonists, especially for blood samples anticoagulated with hirudin or Na-citrate. The largest difference in reference intervals for whole-blood platelet aggregation was noted for site 3. Interestingly, the ethnic diversity captured at this site was more heavily weighted toward Asian participants (38% [24/63]) compared with site 2 (16%) and site 1 (0%). 
Precision Testing
Each site collected blood from healthy volunteers and participants who had ingested aspirin, using all three anticoagulants. Precision testing was performed by analyzing each blood sample with all seven agonists twice in each of five aggregometer channels, for a total of 10 runs per Multiplate analyzer. This was done to ensure the precision of the analyzer and to determine if channel-to-channel variability existed. Due to the length of time required to perform precision testing and the stability of platelet function, not all agonist and anticoagulant combinations could be tested on the same whole-blood sample.
Platelet Aggregation
Platelet aggregation was conducted on the whole-blood five-channel Multiplate platelet analyzer (software version 2.03, Roche Diagnostics) by using impedance aggregometry. This system uses test cells that contain two parallel pairs of electrodes. The metal sensors are made of highly conductive silver-coated copper. Activated platelets adhere and aggregate on the metal sensor wires, resulting in a rise in electrical resistance, which is continuously measured for 6 minutes. Results are expressed in AUC (area under the curve = area under the aggregation curve) units (U) and are recorded against time. The AUC reflects overall platelet activity, which is affected by the height of the aggregation curve.
Agonists tested were ADP (adenosine-5'-diphosphate; final concentration, 6. 
Discussion
Platelet function studies are poorly standardized across and within clinical laboratories. To distinguish true platelet function defects from preanalytical variables, including the effect of anticoagulants used for sample collection, it is important to be able to compare patient results with relevant, robust reference ranges that reflect the ethnic diversity of the local population. This study provides reference ranges from a large number of healthy and ethnically diverse volunteers for platelet aggregation in response to common agonists in blood anticoagulated with three different anticoagulants. Statistically significant (P < .001) differences in reference ranges were noted for blood anticoagulated with Na-citrate, Li-heparin, and hirudin for ADP, ASPI, COL, TRAP, RISTO Hi, RISTO Lo, and ADP HS.
Precision Testing
The goal of precision testing is to determine the maximum allowable %CV at different analyte concentrations. 12 Conducting precision testing on whole-blood platelet aggregation is a challenge due to the short functional life span of platelets in vitro. Guidelines from the Clinical and Laboratory Standards Institute (CLSI) suggest that 10 samples are evaluated in duplicate and that the CVs of the sample pairs are calculated. 13 In this study, we examined repeatability of results, defined as performing the same test by the same operator on one analyzer in one laboratory. Reproducibility was then calculated based on results obtained in the three participating laboratories. Most CVs for whole-blood platelet aggregation were below 17%. Not unexpectedly, the greatest variability in platelet function was seen with RISTO Lo (CV, 11.3%-51.9%) and RISTO Lo in participants who had ingested aspirin (7.5%-71.0%). Comparing anticoagulants, the highest CVs for whole-blood platelet aggregation were noted for blood samples anticoagulated with hirudin, especially when evaluating blood from individuals who had ingested aspirin. These findings are consistent with results of a previous study that examined reproducibility of 59 observations of platelet function in five participants, reporting an average CV of less than 17% for all agonists except RISTO Lo (CV, 42%-160%). 14 evaluating precision can help to determine the validity of patient results and to interpret differences between normal and abnormal results.
Citrate vs Hirudin
Previous studies have demonstrated that anticoagulants used for in vitro platelet function studies may affect platelet responsiveness. Consistent with our findings, work by Wallén et al 6 demonstrated that ADP and COL-induced whole-blood platelet aggregation were significantly lower in blood samples anticoagulated with Na-citrate compared with hirudin. Mean platelet aggregation, expressed as AUC in the present study, for blood samples anticoagulated with Na-citrate was 51.7 for ADP and 68.5 for COL-induced aggregation, compared with 77.5 and 81.7 for ADP and COL-induced platelet aggregation, respectively, in samples anticoagulated with hirudin. These findings support the importance of extracellular calcium for platelet function testing. 6 Comparing results for COL-induced platelet aggregation across studies can be problematic because different COL preparations induce different levels of platelet activation. 15 Similar to findings in the present study, Wallén et al also noted that platelets in blood anticoagulated with heparin demonstrated the highest response to ADP and COL.
Anticoagulant-related differences in platelet reactivity have been reported also in patients receiving antiplatelet therapy. Zhang et al 16 observed differences in whole-blood platelet aggregation using the Multiplate analyzer in patients (n = 119) receiving dual-antiplatelet therapy undergoing coronary stent implantations when blood was collected into Na-citrate vs hirudin. Platelet reactivity with ADP and ASPI was significantly higher than ADP HS in samples anticoagulated with hirudin compared with Na-citrate. This was also noted in the present study using healthy volunteers. Interestingly, this anticoagulant-mediated discrepancy in platelet function was not seen in blood samples obtained from patients following percutaneous coronary intervention. 16 In a reference range study conducted by Rubak et al, 8 RISTO Lo aggregation responses showed greater variability in blood samples anticoagulated with hirudin (AUC, 2.5-25.7) compared with other anticoagulants. This was attributed to the low intrinsic platelet responses to RISTO Lo as opposed to the anticoagulant, since the same effect on platelet function was 8 When reviewing precision for the present study, platelet responses to RISTO Lo in patients who had ingested aspirin showed the highest variability among sites for samples anticoagulated with hirudin (CV, 26%-71%) compared with citrate (CV, 7%-28%). Much lower CVs (≤21%) for the same anticoagulants were noted using RISTO Hi as an agonist.
Citrate vs Heparin
When comparing platelet aggregation results for blood samples anticoagulated with Li-heparin vs Na-citrate, platelet responses to all agonists were lower in the presence of citrate and heparin. Truss et al 17 reported similar findings for blood samples tested with ASPI and COL and attributed the differences to the higher level of extracellular calcium found in heparinized blood (millimolar range) compared with blood anticoagulated with citrate (~50 mmol/L). Extracellular calcium is required to maintain the GPIIb/IIIa complex, 17 which serves as the receptor for fibrinogen and supports platelet aggregation. 18 The authors reported no difference in platelet function in samples tested with TRAP. In contrast, in the present study, increased platelet function was noted in samples anticoagulated with heparin (AUC, 95-171) vs citrate (AUC, 75-137). Although the Multiplate analyzer requires samples collected in Na-citrate to be diluted in saline containing additional calcium to mitigate the effects of calcium chelation, the mean levels of platelet aggregation in response to all agonists in blood anticoagulated with Na-citrate were lower than those for samples anticoagulated with Li-heparin (P < .001). 17 
Heparin vs Hirudin
Anticoagulants such as hirudin and heparin may better preserve ex vivo platelet function. However, heparin may potentiate ADP-induced platelet activation by interacting directly with platelets rather than through its anticoagulant properties. 19, 20 In a study that examined platelet responses to ADP, samples anticoagulated with heparin showed greater platelet reactivity (AUC, 52.1) compared with samples anticoagulated with hirudin (AUC, 35.9) (P = .0015), a relative increase of 65%. In contrast, ADP-induced platelet aggregation in blood collected into Na-citrate (AUC, 24.5) showed a 30.6% decrease in platelet function compared with hirudin. 20 The addition of calcium restored aggregation levels to those observed in blood anticoagulated with hirudin (P = .45). 21 Similar results were obtained in the present study when comparing ADP-induced platelet aggregation for samples anticoagulated with hirudin, Li-heparin, and Na-citrate. AUC results were 88.5, 98.8, and 68.6, respectively.
However, platelet responses to ADP are highly variable, regardless of anticoagulant. This may be because platelet aggregation in response to ADP is more sensitive to preanalytical variables than platelet aggregation induced by other agonists. 22 Physiologic divalent cation concentrations are important for platelet spreading and maximal platelet aggregation measured by impedance platelet aggregometry. 19 Interestingly, platelet function in blood anticoagulated with Li-heparin appears to have decreased stability compared with sodium heparin, due to the competitive interaction between lithium and calcium, as well as the influence of lithium on calcium transport ATPases of the platelet-dense tubular system. 23 
Ethnic Distribution
Of note in this study are apparent differences in results of reference ranges obtained between testing sites. These findings likely reflect differences in ethnicities in the local study populations, particularly the relatively large Asian cohort of one of the sites. Differences occur between white and Asian populations, as well as among ethnically and genetically diverse Asian individuals. 24 Due to small numbers, stratification of reference ranges by ethnic group was not possible in the present study. However, the results suggest the need for relevant reference ranges based on the local population.
Conclusions
Our results indicate that different anticoagulants used to measure platelet aggregation on the Multiplate analyzer lead to statistically significant differences in reference ranges for all agonists tested. These findings affect the comparison of platelet function across studies using different anticoagulants and mandate the establishment of anticoagulant-specific reference ranges. The effect of different anticoagulants on platelet function is also important to note when comparing results across studies.
The strengths of the present reference range study are the number of individuals included in the study (n = 193), the evaluation of platelet function in three different laboratories, and the simultaneous evaluation of platelet function in different anticoagulants. Moreover, precision testing conducted in this study provides insight into analyzer and assay performance in a patient population with normal and abnormal samples. Site-to-site analysis suggests that reference ranges may be transferable if the ethnic distribution of the target population is similar. A potential limitation of the present study is that the evaluation of anticoagulants was restricted to a healthy population, since it is possible that differences between anticoagulants may be more or less pronounced in patients with platelet function defects. In addition, the assumption was made that results from all the sites could be pooled, but significant differences between sites were noted. This may have been due to the inherent variability in platelet aggregation testing or the individual site population. To have sufficient statistical power and achieve 95% confidence intervals, 120 participants at each site should be tested as stated in CLSI guidelines C-28 A3, which define, establish, and verify reference ranges in the clinical laboratory. Nevertheless, having a well-defined, anticoagulant-specific reference range will be important for detecting platelet function defects. This study provides reference ranges that can be validated by clinical laboratories depending on local conditions.
